PT2026775E - Utilização de inibidores da tirosina cinase syk para o tratamento de distúrbios de proliferação celular - Google Patents
Utilização de inibidores da tirosina cinase syk para o tratamento de distúrbios de proliferação celular Download PDFInfo
- Publication number
- PT2026775E PT2026775E PT78048428T PT07804842T PT2026775E PT 2026775 E PT2026775 E PT 2026775E PT 78048428 T PT78048428 T PT 78048428T PT 07804842 T PT07804842 T PT 07804842T PT 2026775 E PT2026775 E PT 2026775E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- tyrosine kinase
- kinase inhibitors
- cell proliferative
- proliferative disorders
- Prior art date
Links
- 102000000551 Syk Kinase Human genes 0.000 title 1
- 108010016672 Syk Kinase Proteins 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79910306P | 2006-05-09 | 2006-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2026775E true PT2026775E (pt) | 2015-08-05 |
Family
ID=38668152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT78048428T PT2026775E (pt) | 2006-05-09 | 2007-05-09 | Utilização de inibidores da tirosina cinase syk para o tratamento de distúrbios de proliferação celular |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20090306214A1 (OSRAM) |
| EP (1) | EP2026775B1 (OSRAM) |
| JP (1) | JP5225264B2 (OSRAM) |
| AU (1) | AU2007246779B2 (OSRAM) |
| CA (1) | CA2651375C (OSRAM) |
| DK (1) | DK2026775T3 (OSRAM) |
| ES (1) | ES2542344T3 (OSRAM) |
| HU (1) | HUE026820T2 (OSRAM) |
| IL (1) | IL195152A (OSRAM) |
| PL (1) | PL2026775T3 (OSRAM) |
| PT (1) | PT2026775E (OSRAM) |
| WO (1) | WO2007129226A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4667870B2 (ja) * | 2002-10-03 | 2011-04-13 | ノヴァレメッド リミテッド | 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物 |
| JP4939396B2 (ja) * | 2004-03-26 | 2012-05-23 | ノヴァレメッド リミテッド | Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法 |
| GB0804213D0 (en) * | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| CN102821761B (zh) * | 2009-09-09 | 2015-06-10 | 诺瓦麦有限公司 | 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺 |
| US8802734B2 (en) * | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| EP3003309B1 (en) | 2013-05-30 | 2020-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3119397B1 (en) | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1908322A (en) * | 1932-04-07 | 1933-05-09 | Claude R Cook | Weed puller |
| US2908691A (en) * | 1958-07-14 | 1959-10-13 | Searle & Co | Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5696270A (en) * | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| JP4667870B2 (ja) * | 2002-10-03 | 2011-04-13 | ノヴァレメッド リミテッド | 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物 |
| JP4939396B2 (ja) * | 2004-03-26 | 2012-05-23 | ノヴァレメッド リミテッド | Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法 |
-
2007
- 2007-05-09 PL PL07804842T patent/PL2026775T3/pl unknown
- 2007-05-09 EP EP07804842.8A patent/EP2026775B1/en not_active Not-in-force
- 2007-05-09 AU AU2007246779A patent/AU2007246779B2/en not_active Ceased
- 2007-05-09 ES ES07804842.8T patent/ES2542344T3/es active Active
- 2007-05-09 DK DK07804842.8T patent/DK2026775T3/en active
- 2007-05-09 US US12/227,104 patent/US20090306214A1/en not_active Abandoned
- 2007-05-09 PT PT78048428T patent/PT2026775E/pt unknown
- 2007-05-09 WO PCT/IB2007/002471 patent/WO2007129226A2/en not_active Ceased
- 2007-05-09 CA CA2651375A patent/CA2651375C/en not_active Expired - Fee Related
- 2007-05-09 HU HUE07804842A patent/HUE026820T2/en unknown
- 2007-05-09 JP JP2009508544A patent/JP5225264B2/ja not_active Expired - Fee Related
-
2008
- 2008-11-06 IL IL195152A patent/IL195152A/en active IP Right Grant
-
2012
- 2012-01-06 US US13/344,976 patent/US20120108666A1/en not_active Abandoned
-
2013
- 2013-10-09 US US14/049,454 patent/US20140039060A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009536191A (ja) | 2009-10-08 |
| WO2007129226A2 (en) | 2007-11-15 |
| IL195152A0 (en) | 2009-09-22 |
| HUE026820T2 (en) | 2016-07-28 |
| ES2542344T3 (es) | 2015-08-04 |
| US20090306214A1 (en) | 2009-12-10 |
| AU2007246779A1 (en) | 2007-11-15 |
| CA2651375C (en) | 2015-12-22 |
| DK2026775T3 (en) | 2015-06-29 |
| PL2026775T3 (pl) | 2015-12-31 |
| JP5225264B2 (ja) | 2013-07-03 |
| IL195152A (en) | 2015-10-29 |
| WO2007129226A3 (en) | 2008-05-08 |
| EP2026775A2 (en) | 2009-02-25 |
| CA2651375A1 (en) | 2007-11-15 |
| EP2026775B1 (en) | 2015-04-29 |
| AU2007246779B2 (en) | 2013-11-28 |
| US20120108666A1 (en) | 2012-05-03 |
| US20140039060A1 (en) | 2014-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL195152A0 (en) | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders | |
| EP2063897A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| EP2063896A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| IL266741A (en) | Broton tyrosine kinase inhibitors | |
| IL201650A0 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| IL196998A0 (en) | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders | |
| IL197933A0 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| IL202505A0 (en) | 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors | |
| AU2009270856A8 (en) | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors | |
| ZA201000106B (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| ZA201000087B (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| PL2120932T3 (pl) | Indazolowe pochodne jako inhibitory kinazy do leczenia raka | |
| IL190935A0 (en) | 4-(3-aminopyrazole)pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | |
| PL2203449T3 (pl) | Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej | |
| PL2197880T3 (pl) | Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej | |
| IL188390A0 (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
| AP2886A (en) | 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders | |
| IL187895A0 (en) | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | |
| IL184997A0 (en) | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis | |
| ZA200901015B (en) | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders | |
| ZA200704735B (en) | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis | |
| ZA201009085B (en) | Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors | |
| ZA200710136B (en) | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | |
| ZA200803582B (en) | 4-(3-Aminopyrazole) Pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | |
| ZA200800409B (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |